Report on Extraordinary General Meeting in NeuroSearch A/S


Announcement
23.10.2012



At the company's Extraordinary General Meeting today, the sale of Huntexil® to Teva Pharmaceutical Industries Ltd. through the fully owned affiliate Ivax International GmbH was approved by the general meeting.

The obtained approval from NeuroSearch shareholders is one of several conditions for the sale of Huntexil®. NeuroSearch will inform the market as soon as the transaction with Teva has been fully completed.


René Schneider
CEO


Contact person:
René Schneider, CEO, telephone: +45 4460 8700 or +45 2911 2097



About NeuroSearch
NeuroSearch A/S (NEUR) is a European-based biopharmaceutical company specialising in CNS diseases. The company is listed on NASDAQ OMX Copenhagen A/S. The company’s product pipeline comprises Huntexil® for the treatment of motor symptoms in patients with Huntington's disease and ordopidine and seridopidine, both of which have completed phase I studies as well as tesofensine for anti-obesity, which is currently in phase II.

NeuroSearch A/S, building

Attachments

Fonds.23-12 - Result of EGM on 23.10.2012 - uk.pdf